<DOC>
	<DOCNO>NCT01926912</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , treatment outcome , appropriate use pattern paliperidone palmitate usage participant schizophrenia hospital setting .</brief_summary>
	<brief_title>A Study Usage Paliperidone Palmitate Patients With Schizophrenia Hospital Setting</brief_title>
	<detailed_description>This prospective ( look forward use periodic observation collect predominantly follow patient enrollment ) , multicenter , observational study ( type study participant observe certain outcomes measure ) . This study consist 6-week observational period data collect participant hospitalize due schizophrenia exacerbation receive treatment paliperidone palmitate ( treatment initiate within 3 week admission hospital ) . The participant satisfaction evaluate week 6 ( early discontinuation ) . Safety evaluation include body weight , extrapyramidal symptom ( eg , inability initiate movement inability remain motionless ) rating scale score , concomitant therapy assessment adverse event .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Participants diagnose schizophrenia Participant admit hospital due exacerbation schizophrenia prior studyrelated activity Participant may , opinion participate physician , benefit treatment paliperidone palmitate initiate within 3 week admission hospital Participant know hypersensitivity paliperidone risperidone Participant previously treat paliperidone palmitate Participant history neuroleptic malignant syndrome Participant clozapine previously treat longacting injectable antipsychotic last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone Palmitate</keyword>
	<keyword>Hospital setting</keyword>
	<keyword>Schizophrenic Disorders</keyword>
</DOC>